Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
Titel:
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
Auteur:
BolaƱos-Meade, Javier Reshef, Ran Fraser, Raphael Fei, Mingwei Abhyankar, Sunil Al-Kadhimi, Zaid Alousi, Amin M Antin, Joseph H Arai, Sally Bickett, Kate Chen, Yi-Bin Damon, Lloyd E Efebera, Yvonne A Geller, Nancy L Giralt, Sergio A Hari, Parameswaran Holtan, Shernan G Horowitz, Mary M Jacobsohn, David A Jones, Richard J Liesveld, Jane L Logan, Brent R MacMillan, Margaret L Mielcarek, Marco Noel, Pierre Pidala, Joseph Porter, David L Pusic, Iskra Sobecks, Ronald Solomon, Scott R Weisdorf, Daniel J Wu, Juan Pasquini, Marcelo C Koreth, John